FDA.reportPublic FDA data

Xylocaine

Product NDC
63323-488
11-digit product format
633230488
Labeler code
63323
Product ID
63323-488_ea480a68-5927-4278-9deb-2956961da428
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE
Dosage form
INJECTION, SOLUTION
Route
EPIDURAL; INFILTRATION; INTRACAUDAL; PERINEURAL
Labeler
Fresenius Kabi USA, LLC
Application
NDA006488
Marketing category
NDA
Marketing start
2010-08-12
Substance
EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE ANHYDROUS
Active strength
.005; 15 mg/mL; mg/mL
Pharmacologic classes
Adrenergic alpha-Agonists [MoA], Adrenergic beta-Agonists [MoA], Amide Local Anesthetic [EPC], Amides [CS], Antiarrhythmic [EPC], Catecholamine [EPC], Catecholamines [CS], Local Anesthesia [PE], alpha-Adrenergic Agonist [EPC], beta-Adrenergic Agonist [EPC]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N006488-002XYLOCAINELIDOCAINE HYDROCHLORIDE2%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-003XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.01MG/ML;2%INJECTABLE / INJECTIONRLD, Approved before 1982
N006488-004XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.01MG/ML;1%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-005XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.02MG/ML;2%INJECTABLE / INJECTIONRLD, RS, Approved before 1982
N006488-007XYLOCAINELIDOCAINE HYDROCHLORIDE1%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-008XYLOCAINELIDOCAINE HYDROCHLORIDE0.5%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-010XYLOCAINELIDOCAINE HYDROCHLORIDE1.5%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-012XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.005MG/ML;0.5%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-017XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.005MG/ML;1.5%INJECTABLE / INJECTIONAPRLD, RS, Approved before 1982
N006488-018XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.005MG/ML;1%INJECTABLE / INJECTIONRLD, RS1986-11-13
N006488-019XYLOCAINE W/ EPINEPHRINEEPINEPHRINE; LIDOCAINE HYDROCHLORIDE0.005MG/ML;2%INJECTABLE / INJECTIONAPRLD, RS1986-11-13

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
N006488-002AP
N006488-004AP
N006488-007AP
N006488-008AP
N006488-010AP
N006488-012AP
N006488-017AP
N006488-019AP

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
XylocaineLIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATEFresenius Kabi USA, LLCba082c2f-64f4-419d-9c88-74f203316e172021-08-25Warnings, Adverse reactionsExact identifier

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

warnings

WARNINGS XYLOCAINE INJECTIONS FOR INFILTRATION AND NERVE BLOCK SHOULD BE EMPLOYED ONLY BY CLINICIANS WHO ARE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF DOSE-RELATED TOXICITY AND OTHER ACUTE EMERGENCIES THAT MIGHT ARISE FROM THE BLOCK TO BE EMPLOYED AND THEN ONLY AFTER ENSURING THE IMMEDIATE AVAILABILITY OF OXYGEN, OTHER RESUSCITATIVE DRUGS, CARDIOPULMONARY EQUIPMENT AND THE PERSONNEL NEEDED FOR PROPER MANAGEMENT OF TOXIC REACTIONS AND RELATED EMERGENCIES (see also ADVERSE REACTIONS and PRECAUTIONS ). DELAY IN PROPER MANAGEMENT OF DOSE-RELATED TOXICITY, UNDERVENTILATION FROM ANY CAUSE AND/OR ALTERED SENSITIVITY MAY LEAD TO THE DEVELOPMENT OF ACIDOSIS, CARDIAC ARREST AND, POSSIBLY, DEATH. Methemoglobinemia Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue Xylocaine and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen. Intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures is an unapproved use, and there have been post-marketing reports of chondrolysis in patients receiving such infusions. The majority of reported cases of chondrolysis have involved the shoulder joint; cases of gleno-humeral chondrolysis have been described in pediatric and adult patients...

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

ADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported: Central Nervous System CNS manifestations are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of lidocaine HCl is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption. Cardiovascular System Cardiovascular manifestations are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest. Allergic Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to local anesthetic agents or to the methylparaben used as a preservative in the multiple dose vials. Allergic reactions, including anaphylactic reactions, may occur as a result of sensitivity to lidocaine, but are infrequent. If allergic reactions do occur, they should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value. There have been no reports of cross sensitivity between lidocaine hydrochloride and procainamide or between lidocaine hydrochloride and quinidine. Neurologic The incidences of adverse reactions associated with the use of loc...

adverse reactions

Systemic Adverse experiences following the administration of lidocaine HCl are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage, rapid absorption or inadvertent intravascular injection, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient. Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

Additional Listing Data#

Finished product
Yes
Brand name base
Xylocaine
Brand name suffix
MPF
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
LIDOCAINE HYDROCHLORIDE ANHYDROUS.005 mg/mL
EPINEPHRINE BITARTRATE15 mg/mL

Harmonized Identifiers#

Field, Values table
FieldValues
UniiEC2CNF7XFP, 30Q7KI53AK
Rxcui1010033, 1010035, 1010671, 1010673, 1010688, 1010692, 1010745, 1010749, 1010751, 1010755, 1010759, 1010763, 1010900, 1010902, 1737343, 1737345, 1737562, 1737563, 1737566, 1737567

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
0b4ec9ca-d305-43fc-88dd-7a510313efe0Product name120260105
bb209f42-a85f-4fee-9d3d-c9dded168625Product name120251208
49628fc7-2031-4c28-bd31-0ef3aa8f44a3Product name320251118
cbf85893-59ef-423f-87d4-a573c000a8b9Product name820250731
b5b1095b-40cd-8a9e-b111-502545045b07Product name420250325
e190029e-423b-473c-8e04-2ada59b5b711Product name120250314
860a93dc-4863-49cc-b284-6bbe8191bc48Product name420250214
eaba870a-6a9d-442e-8643-87b3f558a451Product name120250117
e0031c74-3853-42bc-8e10-86dbbe83992eProduct name220231116
f7046b89-2016-499a-adc6-78479172abc6Product name120230425
9b4cf230-fd05-41d5-98c6-5db9ecb27b86Product name120230117
2686d634-e712-4007-8dbf-3d37c6c4d71fProduct name120181121
fa8b5901-e681-426f-82fe-54f6d81ec698Product name420180619
bd49bb86-2d32-4a7a-a594-eeda2e29af42Product name120180118
332d03e4-aa24-4b11-841a-02bf41081920Product name120171221
c08ab52f-2fc8-4409-9d9f-ed8edc0bd070Product name120171221
3becbe78-12d9-4ad2-9b4c-1e36f8d1303aProduct name120170815
68ed98f8-24c2-44a0-944a-6d36e82ce25aProduct name120141222
1cd42bc2-a430-c72b-636d-991b235fbf80Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
63323-488-01XylocaineMPF10 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION1013
63323-488-03XylocaineMPF30 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION3013
63323-488-07XylocaineMPF30 mL in 1 VIAL, SINGLE-DOSEINJECTION, SOLUTION3013
63323-488-17XylocaineMPF25 in 1 TRAYINJECTION, SOLUTION2513
63323-488-31XylocaineMPF5 in 1 CARTONINJECTION, SOLUTION513
63323-488-37XylocaineMPF25 in 1 TRAYINJECTION, SOLUTION2513

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
63323-488-07ML - Milliliter63323-4883ae53bc4-ca37-4a40-ae51-697ff7f942a312021-05-05
63323-488-17ML - Milliliter63323-48818b9fc6a-2197-402d-ba0b-67a7dd50f4a012012-07-24
63323-488-31ML - Milliliter63323-4884c06246a-44de-4b6a-960f-f9e1d7a1095612012-07-24
63323-488-37ML - Milliliter63323-488b5b7fef8-47c2-4529-a097-63972a6a38bc12012-07-24
63323-488-92ML - Milliliter63323-488b0dc8021-2eb0-4ef4-b7b9-6abd2da2a41d12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIIDailyMed labelSPL versionUploaded
EPINEPHRINE BITARTRATEACTIVE INGREDIENT30Q7KI53AKXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
LIDOCAINE HYDROCHLORIDE ANHYDROUSACTIVE INGREDIENTEC2CNF7XFPXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
EPINEPHRINEACTIVE MOIETYYKH834O4BHXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
LIDOCAINEACTIVE MOIETY98PI200987XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
CITRIC ACID MONOHYDRATEINACTIVE INGREDIENT2968PHW8QPXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
HYDROCHLORIC ACIDINACTIVE INGREDIENTQTT17582CBXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
METHYLPARABENINACTIVE INGREDIENTA2I8C7HI9TXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
SODIUM CHLORIDEINACTIVE INGREDIENT451W47IQ8XXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32IXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6
SODIUM METABISULFITEINACTIVE INGREDIENT4VON5FNS3CXYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]6

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
63323-488XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE (LIDOCAINE HYDROCHLORIDE) INJECTION, SOLUTION XYLOCAINE MPF (LIDOCAINE HYDROCHLORIDE,EPINEPHRINE BITARTRATE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC]13Current NDC, Legacy NDC, 6 package rows20210831_ba082c2f-64f4-419d-9c88-74f203316e17.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
1010745lidocaine HCl 0.5 % / EPINEPHrine 1:200,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737343lidocaine HCl 0.5 % in 50 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010900lidocaine HCl 0.5 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010751lidocaine HCl 1 % / EPINEPHrine 1:100,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867938lidocaine HCl 1 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867943lidocaine HCl 1 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737570lidocaine HCl 1 % in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737568lidocaine HCl 1 % in 2 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737562lidocaine HCl 1 % in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737566lidocaine HCl 1 % in 5 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010033lidocaine HCl 1 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867992lidocaine HCl 1.5 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867996lidocaine HCl 1.5 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010759lidocaine HCl 2 % / EPINEPHrine 1:100,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1868028lidocaine HCl 2 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010688lidocaine HCl 2 % / EPINEPHrine 1:200,000 in 20 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737757lidocaine HCl 2 % in 2 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737761lidocaine HCl 2 % in 5 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010671lidocaine HCl 2 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010749Xylocaine 0.5 % / EPINEPHrine 1:200,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737345Xylocaine 0.5 % in 50 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010902Xylocaine 0.5 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010755Xylocaine 1 % / EPINEPHrine 1:100,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867940Xylocaine 1 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867944Xylocaine 1 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737571Xylocaine 1 % in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737569Xylocaine 1 % in 2 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737563Xylocaine 1 % in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737567Xylocaine 1 % in 5 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010035Xylocaine 1 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867993Xylocaine 1.5 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1867997Xylocaine 1.5 % / EPINEPHrine 1:200,000 in 30 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010763Xylocaine 2 % / EPINEPHrine 1:100,000 Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1868029Xylocaine 2 % / EPINEPHrine 1:200,000 in 10 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010692Xylocaine 2 % / EPINEPHrine 1:200,000 in 20 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737758Xylocaine 2 % in 2 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1737762Xylocaine 2 % in 5 ML InjectionPSNba082c2f-64f4-419d-9c88-74f203316e1713
1010673Xylocaine 2 % Injectable SolutionPSNba082c2f-64f4-419d-9c88-74f203316e1713
186794010 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 10 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
186799310 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 15 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
186802910 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
173757110 ML lidocaine hydrochloride 10 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
17375692 ML lidocaine hydrochloride 10 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
17377582 ML lidocaine hydrochloride 20 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
101069220 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
186794430 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 10 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
186799730 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 15 MG/ML Injection [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
173756330 ML lidocaine hydrochloride 10 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
17375675 ML lidocaine hydrochloride 10 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
17377625 ML lidocaine hydrochloride 20 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
173734550 ML lidocaine hydrochloride 5 MG/ML Injection [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010749epinephrine 0.005 MG/ML / lidocaine hydrochloride 5 MG/ML Injectable Solution [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010755epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010763epinephrine 0.01 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable Solution [Xylocaine with Epinephrine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010035lidocaine hydrochloride 10 MG/ML Injectable Solution [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010673lidocaine hydrochloride 20 MG/ML Injectable Solution [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
1010902lidocaine hydrochloride 5 MG/ML Injectable Solution [Xylocaine]SBDba082c2f-64f4-419d-9c88-74f203316e1713
186793810 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
186799210 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 15 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
186802810 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
173757010 ML lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
17375682 ML lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
17377572 ML lidocaine hydrochloride 20 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
101068820 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 20 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
186794330 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
186799630 ML epinephrine 0.005 MG/ML / lidocaine hydrochloride 15 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
173756230 ML lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
17375665 ML lidocaine hydrochloride 10 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
17377615 ML lidocaine hydrochloride 20 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
173734350 ML lidocaine hydrochloride 5 MG/ML InjectionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010745epinephrine 0.005 MG/ML / lidocaine hydrochloride 5 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010751epinephrine 0.01 MG/ML / lidocaine hydrochloride 10 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010759epinephrine 0.01 MG/ML / lidocaine hydrochloride 20 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010033lidocaine hydrochloride 10 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010671lidocaine hydrochloride 20 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
1010900lidocaine hydrochloride 5 MG/ML Injectable SolutionSCDba082c2f-64f4-419d-9c88-74f203316e1713
173757110 ML Xylocaine 10 MG/ML InjectionSYba082c2f-64f4-419d-9c88-74f203316e1713
17375692 ML Xylocaine 10 MG/ML InjectionSYba082c2f-64f4-419d-9c88-74f203316e1713
17377582 ML Xylocaine 20 MG/ML InjectionSYba082c2f-64f4-419d-9c88-74f203316e1713
173756330 ML Xylocaine 10 MG/ML InjectionSYba082c2f-64f4-419d-9c88-74f203316e1713

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionUnitsMarketing startMarketing endSampleExclude flagStatus
63323-488-016332304880110 mL in 1 VIAL, SINGLE-DOSE10 mlHistorical
63323-488-036332304880330 mL in 1 VIAL, SINGLE-DOSE30 mlHistorical
63323-488-076332304880730 mL in 1 VIAL, SINGLE-DOSE30 mlHistorical
63323-488-176332304881725 VIAL, SINGLE-DOSE in 1 TRAY (63323-488-17) / 10 mL in 1 VIAL, SINGLE-DOSE (63323-488-01) 2010-08-120000-00-00NoNoCurrent
63323-488-31633230488315 VIAL, SINGLE-DOSE in 1 CARTON (63323-488-31) / 30 mL in 1 VIAL, SINGLE-DOSE (63323-488-03) 2010-08-120000-00-00NoNoCurrent
63323-488-376332304883725 VIAL, SINGLE-DOSE in 1 TRAY (63323-488-37) / 30 mL in 1 VIAL, SINGLE-DOSE (63323-488-07) 2010-08-120000-00-00NoNoCurrent